Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

@article{Mato2017OptimalSO,
  title={Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.},
  author={Anthony R Mato and Brian T. Hill and Nicole Lamanna and Paul M Barr and Chaitra Ujjani and Danielle M U Brander and Christina Howlett and Alan Skarbnik and Bruce D Cheson and Clive S Zent and Jeffrey Jiayu Pu and Pavel Kiselev and Kenneth A. Foon and Justin Lenhart and S Henick Bachow and Allison Winter and A-L Cruz and David F. Claxton and Andre H. Goy and Catherine L Daniel and Kristen Isaac and Kaitlin H. Kennard and Colleen Timlin and Michael Fanning and Lisa M. Gashonia and Melissa N Yacur and Jakub Svoboda and Stephen J. Schuster and Chadi Nabhan},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2017}
}
Background Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence. Patients and methods We conducted a multicenter, retrospective analysis of CLL patients treated with kinase inhibitors (KIs) or venetoclax. We examined demographics, discontinuation reasons, overall response rates (ORR), survival, and post-KI salvage strategies. Primary endpoint was progression-free survival (PFS). Results… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS